Centrally acting antiadrenergic (versus unexposed) updated on 03-11-2025

Neonatal medical care

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S13880
R54304		 Kayser - Methyldopa, 2020 Postnatal respiratory disorder days before delivery prospective cohort unexposed, disease free Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified 1.52 [0.81;2.83] C 16/199   32/588 48 199
ref
Total 1 studies 1.52 [0.81;2.83] 48 199
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Kayser - Methyldopa, 2020Kayser - Methyldopa, 2020 1.52[0.81; 2.83]481990%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate0.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.52[0.81; 2.83]48199 -NAKayser - Methyldopa, 2020 1 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.52[0.81; 2.83]48199 -NAKayser - Methyldopa, 2020 1 Tags Adjustment   - No  - No 1.52[0.81; 2.83]48199 -NAKayser - Methyldopa, 2020 1 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 1.52[0.81; 2.83]48199 -NAKayser - Methyldopa, 2020 1 All studiesAll studies 1.52[0.81; 2.83]48199 -NAKayser - Methyldopa, 2020 10.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.52[0.81; 2.83]48199 -NAKayser - Methyldopa, 2020 10.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Firoz (Methyldopa) (Admission to Neonatal int ...Firoz (Methyldopa) (Admission to Neonatal intensive care unit (versus Labetalol)) 0.94[0.58; 1.52]NA-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT1 Abalos (Admission to neonatal or intensive ca ...Abalos (Admission to neonatal or intensive care nursery (RCT versus no antihypertensive drugs/placebo)) 1.56[0.88; 2.78]0%-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT2 Bone - Methyldopa - GESTATIONAL HYPERTENSION ...Bone - Methyldopa - GESTATIONAL HYPERTENSION (Neonatal care unit admission) 0.97[0.50; 1.86]31%-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 Bone - Methyldopa - GESTATIONAL HYPERTENSION ...Bone - Methyldopa - GESTATIONAL HYPERTENSION (Neonatal care unit admission (versus beta-blockers)) 1.39[0.55; 3.70]33%-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 metaPregmetaPreg 1.52[0.81; 2.83]NaN%199----Kayser - Methyldopa, 2020 10.510.01.0